{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:26:33Z","timestamp":1785425193383,"version":"3.56.0"},"reference-count":21,"publisher":"MJH Life Sciences","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"abstract":"<jats:p>BACKGROUND:\nPatients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs), alone or in combination with tyrosine kinase inhibitors (TKIs), often experience significant treatment-related adverse events, including fatigue, that can impair health-related quality of life (HRQOL). Structured exercise interventions may mitigate these symptoms, but data in mRCC are limited.\n\nOBJECTIVE:\nTo evaluate the feasibility and impact of a 12-week supervised remote exercise program on HRQOL, fatigue, and symptom burden in patients with mRCC receiving ICIs or ICI-TKI combinations.\n\nMETHODS:\nNineteen patients with mRCC (median age 67 years; 57.9% male) participated in a 12-week home-based exercise program, supervised via telehealth. The program included aerobic, resistance, and mobility exercises delivered through weekly virtual consultations and supported by the Vedius platform. Outcomes were assessed at baseline and post intervention using the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM), Brief Fatigue Inventory (BFI), and Edmonton Symptom Assessment System (ESAS).\n\nRESULTS:\nParticipants demonstrated significant improvements in overall HRQOL (FACT-General mean increase, 9.8 points; P \u2009=\u2009.001; Cohen d \u2009=\u20090.8), treatment-related toxicity (ICM mean increase, 10.1 points; P \u2009=\u2009.017), and fatigue (BFI mean decrease, 21.1 points; P \u2009=\u2009.018; ESAS fatigue mean decrease, 5.0 points; P \u2009=\u2009.001; Cohen d \u2009=\u2009-1.5). Symptom burden (ESAS mean decrease, 12.3; P \u2009=\u2009.001) and key patient-reported outcomes, including anxiety, depression, appetite loss, and sleep disturbances, also improved ( P \u2009\u2264\u2009.02).\n\nCONCLUSIONS:\nA 12-week supervised remote exercise program was feasible and associated with meaningful improvements in HRQOL, fatigue, and symptom burden among patients with mRCC undergoing ICI-based therapies. These findings support the integration of structured exercise into supportive care for mRCC, highlighting the potential of remote interventions to enhance physical and emotional well-being. Future studies should confirm these results in larger randomized trials and identify the most effective program components.<\/jats:p>","DOI":"10.46883\/2026.25921060","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:15:26Z","timestamp":1771355726000},"page":"44","source":"Crossref","is-referenced-by-count":0,"title":["Remote Exercise Program for Patients With Metastatic Renal Cell Carcinoma Undergoing Immunotherapy: An EXIO Case Series Report"],"prefix":"10.46883","volume":"40","author":[{"given":"Paulo Gustavo","family":"Bergerot","sequence":"first","affiliation":[{"name":"Oncocl\u00ednicas&Co - Medica Scientia Innovation Research (MEDSIR)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Decat","family":"Bergerot","sequence":"additional","affiliation":[{"name":"Oncocl\u00ednicas&Co - Medica Scientia Innovation Research (MEDSIR)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn H.","family":"Schmitz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01z1vct10","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25947","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370-1385. doi:10.1016\/S1470-2045(19)30413-9","DOI":"10.1016\/S1470-2045(19)30413-9"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.Grimm MO, Esteban E, Barth\u00e9l\u00e9my P, et al. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023;24(11):1252-1265. doi:10.1016\/S1470-2045(23)00449-7","DOI":"10.1016\/S1470-2045(23)00449-7"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35(34):3851-3858. doi:10.1200\/JCO.2016.72.1985","DOI":"10.1200\/JCO.2016.72.1985"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.McGregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review. Cancer Treat Rev. 2022;103:102333. doi:10.1016\/j.ctrv.2021.102333","DOI":"10.1016\/j.ctrv.2021.102333"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888-898. doi:10.1016\/S1470-2045(22)00290-X","DOI":"10.1016\/S1470-2045(22)00290-X"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.Massari F, Mollica V, Rizzo A, Cosmai L, Rizzo M, Porta C. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(10):1329-1338. doi:10.1080\/14740338.2020.1811226","DOI":"10.1080\/14740338.2020.1811226"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.Verheijden RJ, Caban\u00e9 Ballester A, Smit KC, et al. Physical activity and checkpoint inhibition: association with toxicity and survival. J Natl Cancer Inst. 2024;116(4):573-579. doi:10.1093\/jnci\/djad245","DOI":"10.1093\/jnci\/djad245"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.Bergerot PG, Bergerot CD, Silva JRG, et al. Exercising and immuno-oncology treatment (ExIO): a prospective pilot study for patients with solid tumors. Support Care Cancer. 2024;32(12):840. doi:10.1007\/s00520-024-09056-3","DOI":"10.1007\/s00520-024-09056-3"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375-2390. doi:10.1249\/MSS.0000000000002116","DOI":"10.1249\/MSS.0000000000002116"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO Guideline. J Clin Oncol. 2022;40(22):2491-2507. doi:10.1200\/JCO.22.00687","DOI":"10.1200\/JCO.22.00687"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.Powles T, Plimack ER, Souli\u00e8res D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563-1573. doi:10.1016\/S1470-2045(20)30436-8","DOI":"10.1016\/S1470-2045(20)30436-8"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.Khosravi N, Stoner L, Farajivafa V, Hanson ED. Exercise training, circulating cytokine levels and immune function in cancer survivors: a meta-analysis. Brain Behav Immun. 2019;81:92-104. doi:10.1016\/j.bbi.2019.08.187","DOI":"10.1016\/j.bbi.2019.08.187"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.Wang J, He Y, Kim AR, Lee KH, Choi SW. Effects of different types of exercise on inflammatory markers in cancer patients: a systematic review and Bayesian network meta-analysis. J Sports Sci. 2025;43(12):1121-1138. doi:10.1080\/02640414.2025.2486886","DOI":"10.1080\/02640414.2025.2486886"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.Raun SH, Buch-Larsen K, Schwarz P, Sylow L. Exercise-a panacea of metabolic dysregulation in cancer: physiological and molecular insights. Int J Mol Sci. 2021;22(7):3469. doi:10.3390\/ijms22073469","DOI":"10.3390\/ijms22073469"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.Larson EA, Dalamaga M, Magkos F. The role of exercise in obesity-related cancers: current evidence and biological mechanisms. Semin Cancer Biol. 2023;91:16-26. doi:10.1016\/j.semcancer.2023.02.008","DOI":"10.1016\/j.semcancer.2023.02.008"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.Zhu C, Ma H, He A, Li Y, He C, Xia Y. Exercise in cancer prevention and anticancer therapy: efficacy, molecular mechanisms and clinical information. Cancer Lett. 2022;544:215814. doi:10.1016\/j.canlet.2022.215814","DOI":"10.1016\/j.canlet.2022.215814"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.Scott JM, Zabor EC, Schwitzer E, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36(22):2297-2305. doi:10.1200\/JCO.2017.77.5809","DOI":"10.1200\/JCO.2017.77.5809"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139(21):e997-e1012. doi:10.1161\/CIR.0000000000000679","DOI":"10.1161\/CIR.0000000000000679"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.Rock CL, Thomson CA, Sullivan KR, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022;72(3):230-262. doi:10.3322\/caac.21719","DOI":"10.3322\/caac.21721"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375-2390. doi:10.1249\/MSS.0000000000002116","DOI":"10.1249\/MSS.0000000000002116"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409-1426. doi:10.1249\/MSS.0b013e3181e0c112","DOI":"10.1249\/MSS.0b013e3181e0c112"}],"container-title":["ONCOLOGY"],"original-title":[],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:15:30Z","timestamp":1771355730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/remote-exercise-program-for-patients-with-metastatic-renal-cell-carcinoma-undergoing-immunotherapy-an-exio-case-series-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.46883\/2026.25921060","relation":{},"ISSN":["0890-9091","2767-7389"],"issn-type":[{"value":"0890-9091","type":"print"},{"value":"2767-7389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}